Acadia Pharmaceuticals Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124.9M | $17.3M | $61.0K | $120.0K | $1.1M | $4.9M | $2.1M | $42.1M |
| NUPLAZID | — | — | — | — | — | — | — | — |
| DAYBUE | — | — | — | — | — | — | — | — |
| Cost of Revenue | $9.1M | $3.1M | — | — | — | — | — | — |
| Gross Profit | $115.8M | $14.3M | — | — | — | — | — | — |
| Gross Margin | 92.7% | 82.2% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $149.2M | $99.3M | $73.9M | $60.6M | $26.7M | $18.8M | $17.3M | $20.6M |
| SG&A Expense | $255.1M | $186.5M | $88.3M | $32.7M | $12.7M | $7.0M | $7.6M | $6.5M |
| Operating Income | $-292.4M | $-272.8M | $-164.6M | $-93.2M | $-38.3M | $-20.9M | $-22.9M | $15.1M |
| Operating Margin | -234.1% | -1,574.1% | -269,855.7% | -77,691.7% | -3,344.7% | -425.6% | -1,105.6% | 35.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-288.3M | $-270.1M | $-164.1M | $-92.5M | $-37.9M | — | — | — |
| Income Tax Expense | $1.1M | $1.3M | $330.0K | $0 | $0 | $0 | $17.0K | $12.0K |
| Net Income | $-289.4M | $-271.4M | $-164.4M | $-92.5M | $-37.9M | $-20.8M | $-22.8M | $15.1M |
| Net Margin | -231.7% | -1,565.9% | -269,578.7% | -77,062.5% | -3,314.2% | -424.9% | -1,101.4% | 35.9% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 125.28B | 122.22B | 102.65B | 100.75B | 91.74B | 55.50B | 52.55B | 38.86B |
| Shares Outstanding (Diluted) | 125.28B | 122.22B | 102.65B | 100.75B | 91.74B | 55.50B | 52.55B | 38.99B |
| Dividends Per Share | — | — | — | — | — | — | — | — |